在胰腺癌中,PRMT1促进与获得的化学抵抗相关的表观遗传重编程
Chan D K Nguyen1, Benjamín A Colón-Emeric1, Shigekazu Murakami1
1Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Cell reports
|May 1, 2024
概括
蛋白质氨酸甲基转移酶1 (PRMT1) 通过改变表观遗传学来驱动胰腺癌的化学抵抗. 抑制PRMT1使胰腺管腺癌细胞对化疗重新敏感,提供了一种新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 胰腺管道腺癌 (PDAC) 由于耐化疗,表现不佳.
- 在PDAC中获得的化学抵抗涉及全球表观遗传重编程.
研究的目的:
- 调查蛋白质氨酸甲基转移酶1 (PRMT1) 在PDAC化学抵抗中的作用.
- 阐明 PRMT1 介导的化学抵抗背后的表观遗传机制.
主要方法:
- 在PDAC模型中利用了PRMT1的遗传和药理抑制.
- 进行了Cut&Tag染色体分析,以分析表观遗传修饰和转录因子结合 (H3K27Ac,MAFF,BACH1).
- 评估了PRMT1抑制和MAFF沉默对凝胺化学抵抗的影响.
主要成果:
- 抑制PRMT1损害了适应性表观遗传重编程,并延迟了对凝胺的获得性耐药性.
- 吉姆西塔治疗诱导了PRMT1的核转位,这限制了MAFF/BACH1复合体的组合.
- PRMT1和MAFF/BACH1特征基因与耐药PDAC异种移植区分为对gemcitabine敏感的基因.
结论:
- PRMT1-MAFF/BACH1轴是PDAC中对gemcitabine表观遗传反应的关键调节者.
- 向PRMT1提供了一种潜在的治疗策略,以提高PDAC患者的化疗疗效率和耐久性.
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K